• Anteris Technologies received German regulatory clearance for its PARADIGM pivotal trial of the DurAVR transcatheter heart valve.
• The clearance enables patient recruitment at German centers for the trial targeting severe calcific aortic stenosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technologies Global Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610192112PRIMZONEFULLFEED9849116) on October 20, 2026, and is solely responsible for the information contained therein.